Eli Lilly announces positive Phase 3 ACHIEVE-4 results for oral GLP-1 Foundayo
Eli Lilly (NYSE:LLY) reached a landmark milestone in its metabolic health pipeline on April 16, 2026, announcing positive topline results from the Phase 3 ACHIEVE-4 clinical trial.










